#1 Clinical Trials Search in Europe

AZD0292

Clinical trials are investigating AZD0292 in people with bronchiectasis and chronic pseudomonas aeruginosa colonization. These studies aim to assess how well AZD0292 works, how safe it is, and how it moves through the body over time. The main focus is on adults with non-cystic fibrosis bronchiectasis and long-term PsA colonization.

Table of Contents

Trial overview

This trial is studying AZD0292 in people with bronchiectasis and chronic pseudomonas aeruginosa colonization.[1]

The trial title says it is designed to learn how well AZD0292 works, how safe it is, and how it moves throughout the body over time.[1]

The brief summary says the study compares IV AZD0292 with placebo to evaluate the effect on the rate of moderate-to-severe pulmonary exacerbations in participants with non-cystic fibrosis bronchiectasis and chronic PsA colonization.[1]

Who is being studied

The target population is people with non-cystic fibrosis bronchiectasis, also called NCFBE, and chronic PsA colonization.[1]

Bronchiectasis is a long-term lung condition in which the airways are damaged and widened, which can lead to repeated infections and flare-ups.[1]

Chronic colonization means the bacteria stay present over time, rather than being a short-term infection.[1]

Trial design and treatment groups

This is an interventional study, which means researchers give a treatment and then measure what happens.[1]

The trial includes two study groups: AZD0292 given as a solution for infusion and placebo for AZD0292.[1]

A placebo is an inactive treatment used for comparison so researchers can better see whether the study drug makes a difference.[1]

The trial is in Phase 2, which is a stage that usually looks more closely at whether a treatment may work while continuing to monitor safety.[1]

The enrollment is 435 participants.[1]

What the trial is measuring

The main endpoint is the annualized rate of exacerbations over a variable follow-up time.[1]

An exacerbation is a worsening of symptoms, and in this trial it refers to moderate-to-severe pulmonary, or lung, flare-ups.[1]

“Annualized rate” means the number of events is measured as a yearly rate, so researchers can compare how often flare-ups happen in the study groups.[1]

The title also says the study will look at how AZD0292 moves throughout the body over time, which is often called pharmacokinetics, but the trial data do not give further details beyond that goal.[1]

Trial status and phase

The trial status is Authorised, which means it has been approved to proceed according to the trial record.[1]

The study phase is Phase 2, so the main focus is on early evidence of benefit and continued safety checking in a defined patient group.[1]

Based on the trial record, this is currently the only listed study of AZD0292 in the provided data.[1]

Trial ID Phase Condition studied Status Enrollment
2025-523009-14-00 Phase 2 Bronchiectasis with chronic pseudomonas aeruginosa colonization Authorised 435

FAQ

  • What is being studied in AZD0292 clinical trials? The trials are studying AZD0292 compared with placebo in people with bronchiectasis and chronic pseudomonas aeruginosa colonization. The main goal is to see whether AZD0292 can lower the number of moderate-to-severe lung flare-ups.
  • Who can take part in these trials? The target group is people with bronchiectasis and chronic PsA colonization. The trial data describe participants with non-cystic fibrosis bronchiectasis, which means bronchiectasis not caused by cystic fibrosis.
  • What phase is the AZD0292 trial? The trial is in Phase 2. This phase usually looks at whether a treatment works and continues checking safety in a larger group than early studies.
  • What condition is the trial focused on? The trial focuses on bronchiectasis with chronic pseudomonas aeruginosa colonization. Bronchiectasis is a long-term lung condition where the airways become widened and damaged, and chronic colonization means the bacteria are present over time.
  • What result is the main trial measuring? The main endpoint is the annualized rate of exacerbations over a variable follow-up time. An exacerbation is a worsening of symptoms, and the study is looking at how often these flare-ups happen over time.

Ongoing Clinical Trials on AZD0292

  • A study to evaluate the safety and effectiveness of AZD0292 in people aged 12 years and older with bronchiectasis and chronic Pseudomonas aeruginosa infection

    Recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark France Germany Greece Italy +2

Glossary

  • Bronchiectasis: A long-term lung disease where the airways become widened and damaged, which can make it easier to get infections and mucus buildup.
  • Non-cystic fibrosis bronchiectasis (NCFBE): Bronchiectasis that is not caused by cystic fibrosis.
  • Pseudomonas aeruginosa (PsA): A type of bacteria that can live in the lungs and may cause ongoing infection or colonization in some people.
  • Chronic colonization: When bacteria stay in the body, such as the lungs, over a long time instead of going away.
  • Placebo: An inactive treatment used for comparison in a trial. It looks like the study treatment but does not contain the active drug.
  • Phase 2: A trial stage that mainly checks whether a treatment may work and continues to study safety.
  • Interventional study: A study where researchers give a treatment and then watch what happens.
  • Exacerbation: A flare-up or worsening of symptoms.
  • Annualized rate: The number of events counted over one year, or adjusted to a yearly rate.
  • Follow-up time: The period when researchers keep checking participants after treatment starts.

References

  1. https://clinicaltrials.gov/study/2025-523009-14-00